Thursday, May 23, 2019

Chondrial Therapeutics, Inc., the Bala Cynwyd-based biopharmaceutical company, has raised $25.8 million to develop treatment for mitochondrial disorders.

THE INQUIRER, phillynews.com. Sam Wood, Updated: May 23, 2019
Chondrial Therapeutics, Inc., the Bala Cynwyd-based biopharmaceutical company, has raised $25.8 million to develop treatment for mitochondrial disorders.
Chondria’s FA therapy has the much-coveted orphan drug designation from the FDA. Chondrial will file an Investigational New Drug application in the next couple of months and go into trials “almost immediately”.